What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside

Pojsakorn Danpanichkul; Kanokphong Suparan; Donghee Kim; Karn Wijarnpreecha

doi:10.3390/jcm13010278

What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside

J Clin Med. 2024 Jan 3;13(1):278. doi: 10.3390/jcm13010278.

Authors

Pojsakorn Danpanichkul¹, Kanokphong Suparan¹, Donghee Kim², Karn Wijarnpreecha^{3

4}

Affiliations

¹ Immunology Unit, Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
² Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA.
³ Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ 85004, USA.
⁴ Department of Internal Medicine, Banner University Medical Center, Phoenix, AZ 85006, USA.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects more than 30% of the world's adult population. While it is associated with obesity and metabolic syndrome, emerging evidence has shown that a substantial number of MASLD patients have a normal body mass index ("lean individuals with MASLD"). In this article, we provide an overview of the definition, epidemiology, pathogenesis, and clinical outcomes associated with lean individuals with MASLD and updates on current management.

Keywords: lean; liver disease; metabolic dysfunction-associated steatotic liver disease; metabolic syndrome.

Publication types

Review

Grants and funding

This research received no external funding.